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We demonstrated the feasibility of a new methodology for isolating colonocytes from feces. To reduce costs and improve the
recoveryrateofcolonocytesfromfeces,weattemptedtodevelopnewimmunomagneticbeads.Severalsizesofmagneticbeadswere
prepared and tagged with a monoclonal antibody against EpCAM. We made several new monoclonal antibodies against EpCAM,
and each monoclonal antibody was tagged to the magnetic beads. In the simulation, the most eﬃcient recovery of HT-29 cells was
obtainedusingthesmallestsizeofbeads.Also,beadstaggedwithamonoclonalantibodywithahigheraﬃnityagainstEpCAMhad
a higher recovery rate. Similar results were obtained when the smallest size of beads with the highest-aﬃnity monoclonal antibody
was applied to clinical samples. The newly developed immunomagnetic beads may be useful for isolating colorectal cancer cells
from feces, enabling the cytological or molecular biological diagnosis of CRC.
Copyright © 2008 Yoshikatsu Koga et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Colorectal cancer (CRC) is one of the most common
malignancies worldwide. CRC is the third leading cause of
cancer-related mortality and the second leading cause of
cancer-related incidence. Nevertheless, the survival rate of
patients with CRC is high if this cancer can be diagnosed
and surgically resected at an early stage [1]. Thus, to reduce
the mortality rate associated with CRC, the development of
a screening test by which early-stage cancers can be detected
is necessary.
The fecal occult blood test has been used widely as a
screening test for CRC [2–4]. However, three recent large-
scale studies have shown that the sensitivity of a fecal occult
blood test was not very high when a total colonoscopy in all
subjects was used as a reference standard [5–7]. Therefore,
several new systems have been developed for diagnosing
colorectal cancer based on the detection of mutated DNA in
feces [8–19]. However, these methods are time consuming
and are not suﬃciently sensitive. The major reason for this
inaccuracy is the fact that nucleic acids in feces are derived
from an enormous number and a variety of bacteria and
normal cells. Accordingly, the proportion of genes derived
from cancer cells in feces is typically as low as 1%, at most
[9]. This makes the clinical application of gene-detecting
methods diﬃcult.
Previously, we reported that cancer cells remain viable in
the feces and can be isolated from naturally evacuated feces
using an immunomagnetic bead methods that we developed
[20, 21]. After extracting DNA from cells isolated from feces,
CRC-relatedgenealterationswereexaminedandadiagnostic
sensitivity of 71% (82/116) and a speciﬁcity of 88% (73/83)
were obtained [21].
Theseﬁgureswererelativelysatisfactory,butthenumbers
of cells isolated from the feces were not very high and, in
addition,commerciallyavailableimmunomagneticbeadsare2 Gastroenterology Research and Practice
Table 1: New immunomagnetic beads.
Beads Size (μm) Antihuman EpCAM antibodies
A3 . 0 V U - 1 D 9
B4 . 9 V U - 1 D 9
C5 . 9 V U - 1 D 9
D3 . 0 C l o n e 1 - 2
E3 . 0 C l o n e B 8 - 4
F3 . 0 C l o n e B 8 - 7
VU-1D9, commercially available EpCAM antibody; clone1-2, clone B8-4,
and clone B8-7 were developed by us in the present study.
relatively expensive. In this context, to improve the function
of immunomagnetic beads for retrieving colonocytes from
naturally evacuated feces and to reduce the cost performance
of this method, we attempted to develop new immunomag-
netic beads and to evaluate their usefulness.
2. MATERIALS AND METHODS
2.1. Immunomagneticbeads
First, we prepared three diﬀerent sizes of magnetic beads
(3.0, 4.9, and 5.9μm). Beads with each diﬀerent size were
tagged with commercially available antihuman EpCAM
monoclonal antibody (mAb), VU-1D9 (AbD Serotec,
Oxford, UK) (see Table 1). Brieﬂy, magnetic beads for cell
separation were prepared from polymer microspheres and
supermagnetic iron oxide extracted from magnetic ﬂuid.
To make magnetic beads with diﬀerent sizes, uniform
polymer microspheres with diameters of 1.8, 3.3, or 3.9μm
were coated with the iron oxide using mechanical shearing
stress. The composite beads were then overcoated with a
hydrophilic polymer layer through the polymerization of
glycidyl methacrylate on the bead. After the hydrolysis of the
polyglycidylmethacrylatelayer,atosylgroupwasintroduced
to the layer as an active group for antibody conjugation.
The sizes of the obtained magnetic beads were determined
to be 3.0, 4.9, and 5.9μm based on electron microscopic
observation (see Figure 1(a)).
Immobilization of the antibody onto the beads was
carried out using a 2-step reaction. First, an antimouse
IgG mAb was coupled to the bead using the amino groups
of the antibody. One hundred micrograms of the goat
antimouse IgG (Fc; Millipore Corporation, Billerica, Ma,
USA) were added to 1mL of 1wt% bead suspension in
0.1M borate buﬀer, pH 9.5, and reacted for 24 hours at
37◦C. Afterthe elimination of uncoupled antibodies through
repeated washing with TBS-T (25mM Tris-buﬀered saline,
pH 7.2, containing 0.01% Tween 20), anti-EpCAM mAb
was immobilized on the bead as a second step. Twenty
micrograms of commercially available anti-EpCAM mAb,
VU-1D9, were added to 1mL of 1wt% bead in TBS-T and
mixed for 1 hour at room temperature. After the reaction,
uncaptured antibody was washed away with TBS-T and
stored at 4◦C until use.
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Figure 1: Simulation to evaluate the recovery rates of colonocytes
using several sizes of beads. (a) Electron microscopy images show 3
diﬀerent sizes of magnetic beads prepared by us. The sizes are 3.0,
4.9, and 5.9μm. Scale bar, 50μm. (b) Comparison of cell recovery
rates. The cell recovery rates using beads A (smallest, 3.0μm), beads
B (medium, 4.9μm), and beads C (largest, 5.9μm) are 65.9±1.37
(%, mean±SD), 61.1±0.98, and 57.1±0.75, respectively. The
columns show the cell retrieval rates and the bars show the standard
deviations. Signiﬁcant diﬀerences are showed by an asterisk (∗,
P = .0001) or a double asterisk (∗∗, P < .0001). (c) Papanicolaou
staining of HT-29 cells captured using immunomagnetic beads.
The arrowheads show the cell-bead complexes. The beads A have
adhered to the HT-29 cells with the highest densely. Scale bar,
50μm.Yoshikatsu Koga et al. 3
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Figure 2: A simulation experiment for the recovery rates of colonocytes depending on the aﬃnity of mAbs. (a) The aﬃnities of newly
developed antihuman EpCAM mAbs are analyzed using ﬂow cytometry. HT-29 cells, which are positive for EpCAM antigen, and UMUC-3
cells, which are negative for EpCAM antigen, are used. The white peak, black peak, dark-gray peak, and light-gray peak show nonspeciﬁc
mouse IgG1 mAb, clone 1-2, clone B8-4, and clone B8-7, respectively. (b) Simulation examining the recovery of the colonocytes. The cell
recovery rates using beads D (tagged with a lower aﬃnity mAb, Clone 1-2), beads E (tagged with a higher aﬃnity mAb, Clone B8-4),
and beads F (tagged with a higher aﬃnity mAb, Clone B8-7) are 4.5±0.98 (%, mean±SD), 73.5±1.96, and 71.2±3.39, respectively.
The columns show the cell retrieval rates and the bars show the standard deviations. Signiﬁcant diﬀerences are showed by an asterisk (∗,
P < .0001).
Next, we developed new antihuman EpCAM mAbs in
order to obtain an antibody with higher aﬃnity against
EpCAM. A recombinant human EpCAM/Fc chimera (R&D
Systems, Minneapolis, Minn, USA) was used as an immuno-
gen. The antigen (0.1mg) was mixed with complete Fre-
und’s adjuvant (Difco, Detroit, Mich, USA) and injected
intraperitoneally (IP) into BALB/c mice (Charles River
Japan, Shizuoka, Japan). Subsequent injections were made
using an RIBI adjuvant system, MPL + DM emulsion
(Corixa, Seattle, Wash, USA) every three weeks for a total
of 7 times. Three weeks later, the mice were given an
intravenous (i.v.) booster injection of 0.1mg of the antigen
in phosphate buﬀered saline. Three days later, spleen cells
from the immunized mice were fused with myeloma cells
(P3X63Ag8.653) at a ratio of 7:1 in 50% polyethylene
glycol 4000 (Sigma, St. Louis, Mo, USA) in RPMI 1640
at room temperature for 1 minute. After centrifugation,
the cells were pelleted, washed, resuspended in RPMI 1640
containing 10% NCTC 109, 20% FCS, and 50ng/L of
mouse IL-6 (R&D Systems), and plated in ﬂat-bottomed
96-well tissue culture palates (Costar Corning, Corning,
NY, USA). Following overnight incubation in a humidiﬁed
5% CO2 atmosphere at 37◦C, hypoxanthine-aminopterin-
thymidine (HAT) medium was added to start HAT selec-
tion. Hybridoma clones were cultured for an additional 8
days, and then the culture media were assayed for speciﬁc
antibody production using the ELISA method on Maxisorp
microtiter plates (Nunc, Roskilde, Denmark) coated with4 Gastroenterology Research and Practice
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Figure 3: Cell retrieval ability of newly developed immunomagnetic beads in clinical samples. (a) Cell retrieval ability using several sized
immunomagnetic beads in clinical samples. The median amounts of DNA from 2-gram stool using beads A (smallest, 3.0μm), beads
B (medium, 4.9μm), and beads C (largest, 5.9μm) are 1.50ng (range; 0.09–8.12), 0.58ng (range; 0–4.23), and 0.25ng (range; 0–4.62),
respectively. The horizontal bar is a median amount of extracted DNA from isolated colonocytes from 2-gram stool; the upper vertical bar
is a maximal amount of extracted DNA; the lower vertical bar is a minimal amount of extracted DNA; and the column contained 50% of
these populations. (b) Cell retrieval ability using immunomagnetic beads tagged with several aﬃnities mAbs in clinical samples. The median
amountsofDNAfrom2-gramstoolusingbeadsD(taggedwithaloweraﬃnitymAb,Clone1-2),beadsE(taggedwithahigheraﬃnitymAb,
Clone B8-4), and beads F (tagged with a higher aﬃnity mAb, Clone B8-7) are 0.75ng (range; 0.03–3.65), 1.66ng (range; 0.12–5.74), and
0.99ng (range; 0.08–5.67), respectively. The horizontal bar is a median amount of extracted DNA from isolated colonocytes from 2-gram
stool; the upper vertical bar is a maximal amount of extracted DNA; the lower vertical bar is a minimal amount of extracted DNA; and the
column contained 50% of these populations.
the antigen. Brieﬂy, an aliquot of undiluted hybridoma
culture supernatant was added to the antigen coated wells.
After 1 hour of incubation and a subsequent wash cycle,
an appropriate dilution of peroxidase-conjugated rabbit IgG
(Bethyl Laboratories, Montgomery, Ala, USA) to mouse IgG
reagent was added. The enzyme-linked IgG binding was
detected using an H2O2 and o-phenylenediamine substrate
solution. The color intensity was measured automatically
using a SpectraMax Plus microplate spectrophotometer
(Molecular Devices, Sunnyvale, Calif, USA). The ELISA
positive hybridoma cells were cloned by limiting dilution in
96-well culture plates and established as stable hybridoma
cells.
TheisotypeofthemAbwasdeterminedusinganMONO
Ab-ID KIT (Zymed, San Francisco, Calif, USA) according to
the manufacturer’s instructions. Ascites ﬂuids were obtained
from pristine-primed CD1-Foxn1nu mice (Charles River
Japan) injected with each mAb producing hybridoma clone.
Immunoglobulin G was separately puriﬁed from each ascites
ﬂuid sample using protein G aﬃnity chromatography (GE
Healthcare Life Science, Piscataway, NJ, USA). The puriﬁed
IgG fractions were used for further characterization and
were evaluated for their reactivity. The immunoglobulin
concentration was determined by measuring the absorbance
at 280nm using an extinction coeﬃcient of 1.38 for mouse
IgG.
The aﬃnities to EpCAM of the newly developed antihu-
manEpCAMmAbswereanalyzedusingﬂowcytometrywith
a BD FACSCalibur (BD, Franklin Lakes, NJ, USA). HT-29
cells and UMUC-3 cells were used as an EpCAM positive
control and negative control, respectively. The antihuman
EpCAM mAbs and nonspeciﬁc mouse IgG1 were directly
labeled using Zenon mouse IgG labeling kits (Molecular
Probes, Eugene, Ore, USA) according to the manufacturer’s
instructions.
Finally, the new antihuman EpCAM mAbs were conju-
gated to the optimal size of magnetic beads chosen in the
present study (see Table 1).
2.2. Simulation
A simulation was conducted to determine the optimal bead
conditions for the recovery of HT-29 colorectal cancer cells
using a previously established method [21]. Brieﬂy, 2-gram
fecal samples were homogenized in a Hanks-HEPES-FBS
buﬀer (40mL) consisting of Hanks solution, 10% fetal
bovine serum (FBS), and 25mM HEPES buﬀer (pH 7.35)
at 200 times per minute for 1 minute using a Stomacher
( S e w a r d ,T h e t f o r d ,U K ) .At o t a lo f1× 105 HT-29 cells were
added to the homogenized solution and ﬁltered through
a nylon ﬁlter (pore size: 512μm). The HT-29 cells were
retrieved using 80μL of several immunomagnetic beads, and
the mixtures were incubated for 30 minutes under gentle
rolling conditions at room temperature. The mixtures on the
magnetwereincubatedonashakingplatformfor15minutes
at room temperature. Then, the supernatant was removed,
and the retrieved cells were counted using a NucleoCounter
( C h e m o M e t e cA / S ,A l l e r ø d ,D e n m a r k ) .
Finally, to determine the optimal immunomagnetic
beads, HT-29 colorectal cancer cells were retrieved using
these immunomagnetic beads, and then the cell-bead com-
plexes were ﬁxed and stained using papanicolaou stain.Yoshikatsu Koga et al. 5
2.3. Patientswithcolorectalcancer
FromMarch2007toJuly2008,40patientswithhistologically
conﬁrmed colorectal cancer were enrolled in the present
study. Nineteen of the 40 patients were enrolled in a study
to analyze the optimal bead size from March 2007 to
September 2007. Then, 21 of the 40 patients were enrolled in
a study to evaluate the quality of the antibody from October
2007 to July 2008. All the patients had undergone surgical
resection of their primary cancer at the National Cancer
Center Hospital, Tokyo, Japan. All patients were thoroughly
informed of the content of the study, and provided their
written consent to participate in the study. The study was
approved by the Institutional Review Board of the National
Cancer Center, Japan.
2.4. Clinicalevaluation
Before surgical resection, naturally evacuated fecal samples
were obtained from patients with colorectal cancer. Each
fecal sample was divided into 2-gram samples for use in the
evaluation of several immunomagnetic beads with diﬀerent
sizes and diﬀerent aﬃnities of the EpCAM antibody. The
fecal samples were prepared as described in the simulation
section. Colonocytes isolated from the feces were stored at
−80◦C until genomic DNA extraction.
Genomic DNA was extracted from colonocytes isolated
from feces using an Allprep mini kit (QIAGEN, Valencia,
Calif, USA) according to the manufacturer’s instructions.
For the genomic DNA analysis, we targeted a consensus
sequence of human Alu repeats. The sequences for the
Alu primers and probe used in this study were as follows:
forward primer, 5 -TAGTAGAGACGGGGTTTCACCTTG-
3 ; reverse primer, 5 -AGCTTGCAGTGAGCCGAGAT-3 ;
probe, 5 -GAGAATGGCGTGAA-3 . The reporter dye at the
5 -end of the probe was FAM, and the quencher dye at the
3 -end was MGB.
The reaction mixture for the genomic DNA analysis
consisted of 4μL of a template DNA, 10μLo fT a q M a n
Fast Universal PCR Master Mix (Applied Biosystems, Foster,
Calif, USA), 500nM of forward and reverse primers, and
2 5 0n Mo fp r o b ei nat o t a lr e a c t i o nv o l u m eo f2 0μL. Real-
time PCR ampliﬁcation wasperformed using precycling heat
activation at 95◦C for 20 seconds, followed by 25 cycles of
denaturation at 95◦C for 3 seconds, and annealing/extension
at 62◦C for 30 seconds in an Applied Biosystems 7500
Fast Real-Time PCR System (Applied Biosystems). The
absolute quantiﬁcation of genomic DNA in each sample
was determined using a standard curve with serial dilutions
( 1 0n gt o1 0 0f g )o fT a q M a nc o n t r o lg e n o m i cD N A( A p p l i e d
Biosystems). A negative control (without template) was run
in each reaction plate.
2.5. Statisticalanalysis
The cell retrieval rate for each group was analyzed using
a Tukey-Kramer multiple comparisons test. Statistical dif-
ferences in the cell retrieval abilities of the new immuno-
magnetic beads were determined using a two-sided Mann-
Whitney U test. Statistical analyses were performed using
StatView Ver. 5 for Windows (Abacus Concepts, Berkeley,
Calif, USA). Values of P < .05 were considered statistically
signiﬁcant.
3. RESULTS
3.1. Recoveryratesofcolonocytesusingseveralsizes
ofmagneticbeadsinthesimulationstudy
We succeeded in preparing three diﬀerent sizes of magnetic
beads. The sizes of beads A, beads B, and beads C were 3.0,
4.9, and 5.9μm, respectively (see Table 1 and Figure 1(a)).
To determine the best size of magnetic beads for cell
recovery, various sizes of magnetic beads were tagged with
a commercially available mAb, VU-1D9 (see Table 1). In
the simulation, the cell recovery rates using beads A, B,
a n dCw e r e6 5 .9 ± 1.37 (%, mean±SD), 61.1 ± 0.98, and
57.1±0.75, respectively. The recovery rate using beads A (the
smallest size) was signiﬁcantly higher than those using beads
B( P = .0001) and beads C (P < .0001) (see Figure 1(b)).
Microscopic observation also showed that the HT-29 cells
were captured using the newly developed immunomagnetic
beads,andthatmoreHT-29cellswereboundtobeadsAthan
to the larger beads B and beads C (see Figure 1(c)).
3.2. Newlydevelopedanti-EpCAM
monoclonalantibodies
We developed three new anti-EpCAM mAbs, named clone
1-2, clone B8-4, and clone B8-7. Flow cytometry analysis
using HT-29 cells (positive for the EpCAM antigen) showed
that the aﬃnity of clone 1-2 was 3 times higher than that
of nonspeciﬁc mouse IgG1, while the aﬃnities of clones B8-
4 and B8-7 were 500 times higher than that of nonspeciﬁc
mouse IgG1 (see Figure 2(a)). The aﬃnity intensities of
clones 1-2, B8-4, and B8-7 to UMUC-3 cells (negative for
EpCAM antigen) were almost identical to that of nonspeciﬁc
mouse IgG1 to UMUC-3 cells. These results show that clone
1-2 was a low-aﬃnity mAb and that clones B8-4 and B8-
7 were high-aﬃnity mAb (see Figure 2(a)). Each antibody
was then conjugated to the optimal size (3.0μm) of magnetic
beads (see Table 1).
3.3. Recoveryrateofcolonocytesdependingon
theafﬁnityofmonoclonalantibodiesagainst
EpCAMinthesimulationstudy
In the simulation, the cell recovery rates using beads D, E,
and F were 4.5 ± 0.98 (%, mean±SD), 73.5 ± 1.96, and
71.2±3.39, respectively. The recovery rate using beads D was
signiﬁcantly lower than those using beads E (P < .0001) and
beads F (P < .0001) (see Figure 2(b)).
3.4. Cellretrievalabilityofnewlydeveloped
immunomagneticbeadsinclinicalsamples
In the clinical study examining cell retrieval ability according
to bead size, the median amount of DNA from 2-gram6 Gastroenterology Research and Practice
stool using beads A, B, and C was 1.50ng (range 0.09–
8.12), 0.58ng (range 0–4.23), and 0.25ng (range 0–4.62),
respectively (see Figure 3(a)). The amount of extracted DNA
using beads A (the smallest beads) was not signiﬁcantly
diﬀerent from that using beads B (P = .09). However, the
amount of extracted DNA using beads A was signiﬁcantly
higher than that using beads C (P = .02). Meanwhile, in
the clinical study examining cell retrieval ability according
to antibody aﬃnity, the median amount of DNA from 2-
gram stool using beads D, E, and F was 0.75ng (range 0.03–
3.65), 1.66ng (range 0.12–5.74), and 0.99ng (range 0.08–
5.67),respectively(seeFigure 3(b)).Theamountofextracted
DNAusingbeadsDwassigniﬁcantlylesscomparedwiththat
using beads E (P = .01).
These results clariﬁed that the smaller immunomagnetic
beads and the beads that were conjugated with higher-
aﬃnity Abs were more eﬃcient at retrieving colonocytes
from feces.
4. DISCUSSION
CRC develops from the colorectal mucosa and therefore
is in continuous contact with feces from an early stage.
Previously,weproposedthatcolorectalcancercellsexfoliated
into the feces might survive for a considerable period in the
feces, since feces do not inhibit cancer expansion towards
the colorectal lumen [20–22]. Meanwhile, we predicted that
normal colorectal mucous cells in contact with the feces
w o u l db ei na na p o p t o t i cs t a g ea n dw o u l dp r o b a b l yb e
exfoliated into the feces. To date, therefore, we have tried
to develop a method by which exfoliated colorectal cancer
cells can be isolated from naturally evacuated feces and then
utilized in cytological or molecular biological diagnosis [21].
In the present study, we developed new immunomagnetic
beadsandevaluatedtheireﬃcienciesintermsoftherecovery
o fe x f o l i a t e dc o l o r e c t a lc a n c e rc e l l si nf e c e sb e c a u s ew eh a d
recognized an urgent need to improve the accuracy of this
method of isolating colonocytes from feces and to reduce the
cost performance.
Intuitively, larger magnetic beads seem more likely to
be attracted to magnetic body, compared with smaller
magnetic beads, since their larger size corresponds to a
greater number of iron particles inside the bead. Therefore,
we initially thought that more cell-bead complexes using
the larger magnetic beads would adhere to the magnetic
body, enabling more cells to be collected. However, in a
study to determine the optimal bead size, the smaller beads
adhered to the HT-29 cells more densely than the larger
beads (see Figure 1(c)). Thus, the total number of cell-bead
complexes attracted to the magnetic body was signiﬁcantly
higher when the smaller beads were used. The cell retrieval
rate using the smaller beads was signiﬁcantly higher than
those using the larger beads (see Figure 1(b)). The results of
an experiment using clinical samples were similar to those
obtained in the simulation (see Figure 3(a)). Consequently,
the smallest beads appeared to collect colonocytes from feces
more eﬃciently than the larger beads.
In our preliminary experiments using a ﬂow cytometry,
it was found that EpCAM antigen was expressed strongly
in human colorectal cancer cell lines, DLD-1, HCT116,
HCT-15, HT-29, LoVo, and SW480. We also analyzed
the positivity of cancer tissue and normal mucosal tissue
using immunohistochemistry. Both the cancer tissues and
the normal mucosal tissues were strongly positive (data
not shown). We then made several mAbs against human
EpCAM and consequently obtained mAbs with either a
high aﬃnity or a low aﬃnity to the EpCAM antigen (see
Figure 2(a)). Each antibody was conjugated to the optimum
(the smallest) beads, and these immunomagnetic beads were
compared with each other. In a simulation using feces
seeded with 1 × 105 HT-29 cells, the cell retrieval rate using
immunomagnetic beads tagged with a high-aﬃnity antibody
was superior to that of the beads tagged with a low-aﬃnity
antibody (see Figure 2(b)). This result indicated that the
higher-aﬃnity antibody tagged to the magnetic beads was
useful for retrieving the cells present in fecal samples. In
addition, the results of a clinical study were similar to the
results of the simulation (see Figure 3(b)).
Previously, we demonstrated the feasibility of a new
methodology for isolating colonocytes from naturally evac-
uated feces, followed by cytological or molecular biological
analysis of the colonocytes to detect colorectal cancer
[21]. An improvement in the immunomagnetic beads was
the most important issue for detecting colorectal cancer
using our diagnostic method. Dynabeads Epithelial Enrich,
immunomagnetic beads for isolating free circulating cancer
cells from serum, was used in our original method. However,
immunomagnetic beads developed for the collection of
colorectal cancer cells from stool solutions, which contain
large amounts of residual substances, were not available.
Therefore, we decided to develop immunomagnetic beads
designed especially for the isolation of colorectal cancer cells
from feces.
5. CONCLUSIONS
We succeeded in developing suitable immunomagnetic
beads for the isolation of colonocytes from feces. The
new immunomagnetic beads, which were 3.0μmi ns i z e
and were conjugated with a new monoclonal antibody
possessing a higher aﬃnity to EpCAM, could eﬀectively
isolate colonocytes from feces. This result is promising for
the future of CRC diagnosis.
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